Significant response to immune checkpoint inhibitor camrelizumab in a heavily pretreated advanced ER+/HER2-breast cancer patient with high tumor mutational burden: a case report
user-5f8cf9244c775ec6fa691c99(2020)
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要